Effects of pegfilgrastim injection: A Synthesis of Findings from 8 Studies

  1. Home
  2. Effects of pegfilgrastim injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of pegfilgrastim injection: A Synthesis of Findings from 8 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of pegfilgrastim injection: A Synthesis of Findings from 8 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Pegfilgrastim is an effective drug for preventing febrile neutropenia in cancer patients undergoing chemotherapy. 6 compared the effectiveness and safety of single-dose pegfilgrastim with daily filgrastim injections in pediatric sarcoma patients receiving chemotherapy. The results showed no significant difference between the two groups. 8 showed that pegfilgrastim is effective in mobilizing CD34(+) stem cells into the peripheral blood of pretreated lymphoma patients undergoing chemotherapy. 5 demonstrated that single-dose pegfilgrastim is as effective as daily filgrastim injections in reducing the duration of febrile neutropenia in lymphoma and myeloma patients who have undergone autologous stem cell transplantation. 2 evaluated the effectiveness and safety of pegfilgrastim when administered less than two weeks before a subsequent chemotherapy cycle and found that pegfilgrastim maintains its effectiveness and safety even with short intervals between chemotherapy cycles. 4 indicated that a 3.6 mg dose of pegfilgrastim is effective for preventing febrile neutropenia. However, 3 reported a case of a breast cancer patient who experienced leukocytosis and fatigue after pegfilgrastim injections, and these symptoms improved after reducing the dosage.

Benefits and Risks

Benefits Summary

Pegfilgrastim is an effective drug for preventing febrile neutropenia in cancer patients undergoing chemotherapy. 6 compared the effectiveness and safety of single-dose pegfilgrastim with daily filgrastim injections in pediatric sarcoma patients receiving chemotherapy. The results showed no significant difference between the two groups. 8 showed that pegfilgrastim is effective in mobilizing CD34(+) stem cells into the peripheral blood of pretreated lymphoma patients undergoing chemotherapy. 5 demonstrated that single-dose pegfilgrastim is as effective as daily filgrastim injections in reducing the duration of febrile neutropenia in lymphoma and myeloma patients who have undergone autologous stem cell transplantation. 2 evaluated the effectiveness and safety of pegfilgrastim when administered less than two weeks before a subsequent chemotherapy cycle and found that pegfilgrastim maintains its effectiveness and safety even with short intervals between chemotherapy cycles.

Risks Summary

Pegfilgrastim may cause side effects such as leukocytosis, fatigue, bone pain, and muscle pain. 3 reported a case of a breast cancer patient who experienced leukocytosis and fatigue after pegfilgrastim injections, and these symptoms improved after reducing the dosage.

Comparison between Studies

Commonalities

Multiple studies have shown that pegfilgrastim is effective in preventing febrile neutropenia in cancer patients undergoing chemotherapy. Several studies have also indicated that pegfilgrastim is superior to filgrastim in preventing febrile neutropenia.

Differences

The dosage of pegfilgrastim varies depending on the study. 6 administered a single dose of 100 mcg/kg of pegfilgrastim to pediatric sarcoma patients, while 4 administered a 3.6 mg dose to breast cancer patients. The timing of pegfilgrastim administration also varies. 6 administered pegfilgrastim after chemotherapy, while 8 administered it concurrently with chemotherapy.

Consistency and Contradictions of Results

Multiple studies have demonstrated the effectiveness of pegfilgrastim in preventing febrile neutropenia in cancer patients undergoing chemotherapy. 6 , 8 , 5 , 2 support this effectiveness. However, 3 reported a case where leukocytosis and fatigue were observed after pegfilgrastim administration, and these symptoms improved after dosage reduction. These results suggest that while pegfilgrastim is an effective drug, it is essential to consider the risk of side effects.

Precautions for Real-Life Application

Pegfilgrastim is an effective drug for preventing febrile neutropenia in cancer patients undergoing chemotherapy. However, it is crucial to consider the risk of side effects. 3 reported a case where leukocytosis and fatigue were observed after pegfilgrastim administration, and these symptoms improved after dosage reduction. When taking pegfilgrastim, it is vital to consult with a physician to understand the risks and benefits of the drug and determine the appropriate dosage and administration method.

Current Limitations of Research

Research on pegfilgrastim is still insufficient, particularly regarding its long-term effects. Additionally, the dosage and administration methods of pegfilgrastim vary among patients, requiring further research to identify the optimal administration approach.

Future Research Directions

Future research is necessary to investigate the long-term effects of pegfilgrastim, determine the optimal administration methods, and understand interactions between pegfilgrastim and other drugs.

Conclusion

Pegfilgrastim is an effective drug for preventing febrile neutropenia in cancer patients undergoing chemotherapy. However, it is crucial to consider the risk of side effects. When taking pegfilgrastim, it is vital to consult with a physician to understand the risks and benefits of the drug and determine the appropriate dosage and administration method. Further research on pegfilgrastim is expected to lead to a more secure and effective administration approach in the future.

Literature analysis of 8 papers
Positive Content
6
Neutral Content
2
Negative Content
0
Article Type
3
0
0
0
8
1.

Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers.

Author: SiéP, AlbaredeJ L, RobertM, BoulouxC, LansenJ, ChigotC, CorrellS, ThouvenotJ P, BoneuB

Good tolerance
Liver enzyme elevation
Platelet reduction

Pentosan polysulfate (PPS) is a drug that can be used to treat certain medical conditions. This study investigated the tolerance and pharmacological activity of PPS in 30 healthy volunteers. PPS was well tolerated, with the most common side effects being increased transaminase levels and decreased platelet counts. The study found that PPS significantly prolonged the activated partial thromboplastin time (APTT) and induced a weak but significant circulating anti-Xa activity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Evaluation of efficacy and safety of pegfilgrastim when given less than two weeks from dose-dense chemotherapy regimens.

Author: UmoruGodsfavour O, ZaghloulHanna, El-RahiCynthia, EnsorJoe E

This study evaluated the practice related to the use of pegfilgrastim, a drug used to stimulate white blood cell production, in oncology patients.

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan.

Author: MoritaSachi, KikumoriToyone, TsunodaNobuyuki, InaishiTakahiro, AdachiYayoi, OtaAkiko, ShibataMasahiro, MatsuokaAyumu, NakanishiKenichi, TakeuchiDai, MizutaniTakefumi, ShimokataTomoya, HayashiHironori, MaedaOsamu, AndoYuichi

Breast cancer survival
Hematotoxicity
Pegfilgrastim dose reduction

Dose-dense chemotherapy with epirubicin and cyclophosphamide (EC) was feasible when supported by a lower dose of pegfilgrastim (3.6 mg) in Japan. Relative dose intensity (RDI) and safety were comparable to those observed with a higher dose (6.0 mg), suggesting that this approach is a viable alternative for dose-dense EC treatment.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).

Author: SebbanC, LefrancA, PerrierL, MoreauP, EspinouseD, SchmidtA, KammounL, GhesquieresH, FerlayC, BayJ O, LissandreS, PérolD, MichalletM, QuittetP

Cost-effectiveness
Reduced duration of febrile neutropenia

A single subcutaneous injection of pegfilgrastim was more effective in reducing the duration of febrile neutropenia compared to daily filgrastim injections after peripheral blood stem cell transplantation in patients receiving high-dose chemotherapy for myeloma and lymphoma.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.

Author: SpuntSheri L, IrvingHelen, FrostJami, SenderLeonard, GuoMatthew, YangBing-Bing, DreilingLyndah, SantanaVictor M

Febrile neutropenia prevention
Neutropenia treatment

This randomized, open-label study compared the efficacy and safety of a single dose of pegfilgrastim with daily filgrastim administration in pediatric patients receiving chemotherapy for sarcoma. Both treatments demonstrated similar efficacy and safety profiles, with pegfilgrastim offering a convenient single-dose administration option.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry.

Author: BeaupainBlandine, LeblancThierry, RemanOumédaly, HermineOlivier, VannierJean-Pierre, SuarezFelipe, LutzPatrick, BordigoniPierre, JourdainAnne, SchoenvaldMichele, OuacheeMarie, FrançoisSylvie, KohserFréderic, JardinFabrice, DevouassouxGilles, BertrandYves, Nove-JosserandRaphaele, DonadieuJean,

Neutrophil count increase
Bone pain
Severe infection

Pegfilgrastim is more difficult to use than conventional GCSF in treating congenital neutropenia. It is associated with more frequent adverse events and sometimes poor efficacy.

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients.

Author: IsidoriAlessandro, TaniMonica, BonifaziFrancesca, ZinzaniPierluigi, CurtiAntonio, MottaMaria Rosa, RizziSimonetta, GiudiceValeria, FareseOriana, RovitoManuela, AlinariLapo, ConteRoberto, BaccaraniMichele, LemoliRoberto M

Mobilize stem cells
Promote engraftment

Pegfilgrastim in combination with salvage chemotherapy is a predictable and highly effective mobilization regimen in pretreated lymphoma patients.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.